Journal of Clinical Oncology, Vol 6, 158-162, Copyright © 1988 by American Society of Clinical Oncology
Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer
B Reichman, M Markman, T Hakes, N Kemeny, D Kelsen, W Hoskins, S Rubin and JL Lewis Jr
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
In an effort to maximize both local-regional and systemic drug exposure to
tumor in the peritoneal cavity, a phase I study was conducted that examined
the simultaneous daily intraperitoneal (IP) and continuous intravenous
infusion (CVI) of fluorouracil (5-FU) to 32 patients with refractory
cancer. IP 5-FU administered at 1,000 mg/d with concurrent 5- FU by CVI at
1,000 mg/m2/d for four consecutive days was well tolerated. One patient
with a primary gastrointestinal (GI) malignancy with minimal volume disease
experienced a surgically defined complete remission. In theory, this
regimen may demonstrate clinical utility as an adjuvant treatment of
certain GI malignancies. Future studies are planned in this clinical
setting.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
